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Gene therapyAbstract Technological advances are important for innovative biological research. Development
of molecular tools for DNA manipulation, such as zinc ﬁnger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs), and the clustered regularly-interspaced short palin-
dromic repeat (CRISPR)/CRISPR-associated (Cas), has revolutionized genome editing. These
approaches can be used to develop potential therapeutic strategies to effectively treat heritable dis-
eases. In the last few years, substantial progress has been made in CRISPR/Cas technology, includ-
ing technical improvements and wide application in many model systems. This review describes
recent advancements in genome editing with a particular focus on CRISPR/Cas, covering the under-
lying principles, technological optimization, and its application in zebraﬁsh and other model organ-
isms, disease modeling, and gene therapy used for personalized medicine.Introduction
Since the discovery of the DNA double helix in 1953, many
basic biological concepts pertaining to the genome, such as
gene transcription and translation, genetic code and epigenetic
modiﬁcation, have been established by developing multiple
experimental techniques. These include enzymes for in vitro
DNA manipulations (such as polymerases, restriction endonu-
cleases, and DNA ligases), recombinant DNA technology,
in vitro DNA synthesis, site-speciﬁc mutagenesis, andwhole-genome sequencing. Nonetheless, site-speciﬁc
modiﬁcation within genomes has remained a major challenge.
Genome editing, namely, refers to editing the nucleotides of
the genome with engineered nucleases in cultured cells or living
organisms. In the past decade, several types of engineered
nucleases have been developed, including zinc ﬁnger nucleases
(ZFNs), transcription activator-like effector nucleases
(TALENs), and the recent clustered regularly-interspaced
short palindromic repeat (CRISPR) systems. These nucleases,
in particular CRISPR systems, immensely facilitate the wide
application of genome editing in various biological research
ﬁelds. More importantly, genome editing holds great promise
in potential clinical applications such as gene therapy. In this
review, we will brieﬂy describe the features and development
of these three editing methods and then mainly focus on the
latest CRISPR technology, Science’s 2015 Breakthrough of
the Year [1], and its application.nces and
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ZFNs were discovered in 1996 and subsequently employed in
genetic engineering experiments with Drosophila and mam-
malian cells in 2002 [2–4]. Unlike the previously reported
approaches relying on DNA base-pair recognition, such as
oligonucleotides, reverse splicing, or small molecules, the
site-directed ZFNs act through DNA/protein recognition
[2,4–7]. ZFNs are composed of a zinc ﬁnger-mediated DNA
binding domain for DNA recognition and a nuclease activity
domain of FokI for DNA cleavage [2]. ZFNs can cause
double-strand DNA breaks (DSBs). Subsequently, insertion
or deletion at the site of the genomic DSB can be induced by
imprecise non-homologous end joining (NHEJ)-mediated
repair, whereas point mutations or insertions from oligonu-
cleotide or plasmid donor templates can be introduced by pre-
cise homology-directed repair (HDR)-mediated repair [8].
Over the past decade, ZFNs were optimized and widely used
in, for example, targeted gene knockout in the genomes of
mammalian cells to generate genetically distinct DHFR/ cell
lines, establishing OCT4-eGFP human embryonic stem cells
(hESCs) or targeting PITX3 in induced pluripotent stem
(iPS) cells, and heritable gene disruption in mouse and
zebraﬁsh [9–12].
TALENs
Plant pathogen Xanthomonas can secret TALEs upon infec-
tion of various host species, which facilitate bacterial infec-
tion or trigger defense by binding to promoter regions to
activate effector-speciﬁc genes or R genes of the host plants
[13,14]. TALEs recognize speciﬁc DNA sequences via
DNA-binding domains composed of nearly identical 34-
amino acid repeated units. Two hypervariable amino acid
residues at positions 12 and 13, named repeat-variable diresi-
dues (RVDs), are required for target site speciﬁcity [15,16].
Therefore, RVDs have been manipulated to generate the pro-
grammable DNA-binding proteins and used for site-directed
genome editing [15–19]. Similar to ZFNs, the sequence-
independent FokI nuclease, found in Flavobacterium okeano-
koites, functions as the site-speciﬁc nuclease for TALEN
assays when the target sites are recognized by different
TALEs.
Due to the high similarity of TALE recognition sequences,
a complicated procedure is required to generate programmable
proteins that target speciﬁc sites on the genomic DNA, which
limits the wide use of TALENs in genome engineering. The
presence of extensive identical repeat sequences confers a huge
technical challenge to clone repeated TALE arrays for
different DNA target sites. To this end, several modiﬁed
methods have been developed to enable rapid TALE assembly,
including the ‘Golden Gate’ platform [20,21], high-throughput
solid-phase based sequential ligation systems [22,23], and
ligation-independent cloning techniques [24]. For target site
recognition, it’s extremely important that the sequence of
the TALE binding sites should start with a thymine (T).
Moreover, the length of the target site and the spacer between
the two TALEN arms are also very important for the
formation of the FokI dimer and editing efﬁciency.CRISPR/Cas
CRISPR/CRISPR-associated (Cas) systems exist in prokar-
yotes to mediate bacterial adaptive immune defense against
viruses or invading nucleic acids, as the ﬁrst infection experi-
ments showed that CRISPR/Cas confer resistance against lytic
phages of Streptococcus thermophilus [25]. Brouns et al. found
that mature CRISPR RNAs (crRNAs) work with Cas proteins
to provide prokaryotes with antiviral defense by interfering
with virus proliferation [26]. In 2012, Jinek et al. showed that
the dual-RNA structure formed by crRNA and trans-
activating crRNA (tracrRNA) is sufﬁcient to direct Strepto-
coccus pyogenes type II Cas9 protein (spCas9) to cleave speciﬁc
target DNA sequences in vitro [27]. In vitro DNA cleavage by
spCas9 and dual-RNAs reveals the potential of this system for
genome editing. Subsequently, the RNA-guided editing tool
for mammalian genomes was established using an engineered
type II bacterial CRISPR system in 2013 [28,29].
In the CRISPR/Cas system, crRNA–tracrRNA, also
referred as the guide RNA (gRNA), recognizes the target sites
on the genome, and then recruits Cas9 protein for precise
cleavage at speciﬁc endogenous genomic loci [28,29]. During
this process, synthesis of the gRNA, composed of a speciﬁc
20-bp crRNA and the universal tracrRNA, can be driven by
a U6 polymerase III promoter in vivo or by a phage RNA
polymerase, such as T7 RNA polymerase, in vitro [29–31].
The ﬁrst nucleotide of the gRNA target site should be a
guanine (G) for U6-directed transcription and two guanines
(GG) for T7-directed transcription [28–31]. The most important
region for target site selection by the CRISPR/Cas system is
the protospacer adjacent motif (PAM) sequence, NGG, which
mediates stimulation of the Cas9 nuclease activity [29]. Thus,
compared to ZFNs and TALENs, the easy programmability
of gRNAs is the most advantageous feature of CRISPR/Cas
system (Table 1). Therefore, CRISPR/Cas has been quickly
applied to generate mutations in different organisms, to
establish various disease models, and for the use in gene
correction and therapy [32].
CRISPR/Cas in model organisms
The modiﬁed type II CRISPR/Cas, including the human
codon–optimized versions of Cas9 and the speciﬁc gRNA,
was ﬁrst shown to work efﬁciently in HEK 293T cells, human
leukemia K562 cell line, murine cell lines, and PGP1 iPS cells,
using the adeno-associated virus integration site 1 (AAVS1) or
empty spiracles homeobox 1 (EMX1) loci as target genes in
February 2013 [28,29]. Soon after, in March 2013, the synthe-
sized Cas9 mRNA and gRNA targeting fumarate hydratase
(fh) were shown to work in vivo to induce targeted genetic
modiﬁcations in zebraﬁsh as efﬁciently as ZFN and TALENs
[33]. A month later, it was reported that Cas9/gRNA efﬁ-
ciently induced biallelic conversion of etsrp and gata5 in zebra-
ﬁsh somatic cells and resulted in the abnormal intersegment
vessels and cardia biﬁda, respectively, recapitulating the phe-
notype of etsrpy11 and fautm236a mutants described previously
[34]. Later on, CRISPR/Cas-mediated gene editing was used
to efﬁciently disrupt ﬁve genes simultaneously in mouse ESCs.
Meanwhile, mice with biallelic mutations in Tet1 and Tet2
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338 Genomics Proteomics Bioinformatics 13 (2015) 336–344were generated by co-injecting Cas9 mRNA and gRNA target-
ing Tet1 and Tet2 into mouse zygotes in May 2013 [30].
In Drosophila, efﬁcient mutagenesis of the yellow gene was
induced by injecting Drosophila embryos with a single guide
RNA (sgRNA) targeting the second exon of the gene, and ani-
mals carrying stable germline mutations were obtained [35].
CRISPR/Cas9 mediated heritable genome editing in
Caenorhabditis elegans was established by Calarco’s group in
August 2013. Expression of Cas9 protein, together with speci-
ﬁc sgRNAs targeting the coding sequences of the unc-119 and
dpy-13 genes, caused insertion or deletion (indels) in these two
genes, and the resulting animals exhibited previously identiﬁed
phenotypes, such as uncoordinated (Unc) and dumpy (Dpy)
[36]. As shown in Figure 1, the CRISPR/Cas system has been
rapidly utilized in an increasing number of model organisms,
including Arabidopsis [37], Nicotiana benthamiana [37], rat
[38], Xenopus tropicalis [39], cynomolgus monkey [40], Plas-
modium falciparum [41], and even in human tripronuclear
zygotes [42].CRISPR/Cas in zebraﬁsh
Zebraﬁsh (Danio rerio) serves as a classic model organism
owing to its unique features, including external fertilization,
transparent embryos, high fecundity, and rapid growth. Tech-
nologies for genome editing, such as ZFNs, TALENs and
CRISPR/Cas, have been applied in zebraﬁsh soon after they
were initially reported (Table 2). fh was the ﬁrst gene to be efﬁ-
ciently engineered in zebraﬁsh using CRISPR/Cas [33], and
then zebraﬁsh-codon-optimized Cas9 was generated to
improve the genome editing efﬁciency [31,43]. Knock-in of
DNA cassettes into the zebraﬁsh genome using CRISPR/
Cas9 was carried out by co-injecting a donor plasmid, together
with the gRNA and a capped Cas9 mRNA, into one-cell stage
embryos. With this convenient approach, speciﬁc zebraﬁsh
eGFP lines, including Tg(neurod:eGFP), Tg(vsx2:eGFP), and
Tg(pou4f3:mGFP), were converted into Gal4 transgenic lines,
which facilitated the creation of reporter or loss-of-function
alleles in zebraﬁsh [44].
CRISPR/Cas9 was also used to facilitate an HA tag knock-
in at the C13H9orf72 (C9t3) locus using a donor oligonu-
cleotide [45]. It was shown that P2A-EGFP was knocked-in
to the endogenous zebraﬁsh tyrosine hydroxylase (th) to trace
th positive cells in vivo using an intron targeting-mediated
and an endogenous gene integrity-maintaining strategy with
the CRISPR/Cas system [46]. Zon’s group generated a
CRISPR/Cas9 vector system for tissue-speciﬁc gene disruption
and the urod gene was disrupted under the control of different
tissue-speciﬁc promoters, mimicking human hepatic cutaneous
porphyria in zebraﬁsh [47]. Interestingly, multiplex-conditional
CRISPR/Cas9-based mutagenesis in zebraﬁsh can be achieved
with Cas9 driven by the heat-shock-inducible or tissue-speciﬁc
promoters and the Golden Gate assembly of sgRNA-
expressing cassettes to allow temporally or spatially restricted
gene inactivation [48]. In addition, CRISPR/Cas was used
in vivo for rapid, reverse genetic screening of 48 loci in zebra-
ﬁsh. As a result, two new genes were demonstrated to be
involved in electrical synapse formation [49]. Taken together,
the application of CRISPR/Cas in zebraﬁsh is becoming
more popular, along with the modiﬁcations to this technology
Figure 1 The timeline for applications of CRISPR/Cas technology in model organisms
Table 2 Genome editing ﬁrstly reported in various biological systems and zebraﬁsh
Technology
First report on genome editing First report on zebraﬁsh
Gene/locus Species/cell line Time Ref. Gene Time Ref.
ZFN Yellow (y) Drosophila Jul, 2002 [3] gol Jun, 2008 [11]
TALENs NTF3 and CCR5 HEK 293, K562 Feb, 2011 [17] tnikb Aug, 2011 [19]
CRISPR/Cas AAVS1 locus HEK 293, K562, and PGP1 iPS cells Feb, 2013 [29] tia1l and gsk3b Mar, 2013 [33]
EMX1 HEK 293 Feb, 2013 [28]
Th loci N2A Feb, 2013 [28]
Note: ZFN, zinc ﬁnger nuclease; TALEN, transcription activator-like effector nuclease; CRISPR, clustered regularly-interspaced short palindromic
repeat; Cas, CRISPR-associated; NTDF3, neurotrophin-3; CCR5, chemokine (C–C motif) receptor 5; AAVS1, adeno-associated virus integration
site 1; EMX1, empty spiracles homeobox 1; Th, tyrosine hydroxylase; gol, golden; tnikb, TRAF2 and NCK-interacting protein kinase; tia1, T-cell-
restricted intracellular antigen-1; gsk3b, glycogen synthase kinase 3 beta.
Figure 2 CRISPR/Cas in zebraﬁsh
Ma D and Liu F /Genome Editing in Model Organisms 339(Figure 2). In the meanwhile, zebraﬁsh has become a useful
model for technical improvement of CRISPR/Cas system.Technological improvement of CRISPR/Cas
So far, CRISPR/Cas has been used in most of the well-
established model organisms. To improve the efﬁciency and
speciﬁcity of the CRISPR/Cas system, different codon-
optimized versions of Cas9 protein have been generated for
different organisms, including human [29], mouse [30,50],and zebraﬁsh [31]. As in vivo genome editing in adult organ-
isms is limited by the cargo size of the adeno-associated virus
(AAV) vector, Zhang’s group identiﬁed shorter Cas9 from S.
thermophilus LMD-9 (St1Cas9) [28] and Staphylococcus aureus
(SaCas9). They went further to engineer these Cas9, together
with gene speciﬁc gRNA, into a single AAV vector to target
the cholesterol regulatory gene Pcsk9 in the mouse liver [51].
They also characterized a new RNA-guided endonuclease
named Cas protein 1 of PreFran subtype (Cpf1). Cpf1 utilizes
a T-rich PAM and exhibits efﬁcient genome-editing activity in
human cells [52]. The studies from Zhang’s lab not only
340 Genomics Proteomics Bioinformatics 13 (2015) 336–344showed direct evidence for genome editing in mammalian cells,
but also improved the efﬁciency, utility, and potential applica-
tions of the CRISPR/Cas system in broad research ﬁelds.Efﬁciency improvement via gDNA modiﬁcation
CRISPR/Cas system was also optimized through gRNA mod-
iﬁcation. Chen’s group developed an optimized CRISPR/Cas
system to achieve high rates of biallelic gene disruption in
zebraﬁsh F0 populations. Besides the zebraﬁsh codon-
optimized Cas9 protein, the sequence of the 30-end of the
crRNA::tracrRNA chimera was modiﬁed to GGAUC instead
of a string of U residues normally found at the end of gRNA
[31]. In following studies, it was found that the use of fewer
than 20 nucleotides for gRNA complementarity could mini-
mize off-target effects without sacriﬁcing on-target genome
editing efﬁciencies [53]. Recently, CRISPR subtype Ypest
protein 4 (Csy4), an endoribonuclease from the bacterium
Pseudomonas aeruginosa, was used to expand genome targeting
sites in human cells and zebraﬁsh [54,55]. In addition,
chemically-modiﬁed gRNAs were shown to increase the
frequency of gene disruption in human primary T cells and
CD34+ hematopoietic stem and progenitor cells (HSPCs)
without evident toxicity [56]. With the codon-optimized
Cas9, the shorter endonucleases, and the modiﬁed gRNA
and expansion sites, CRISPR/Cas will become a common
experimental technique for life science, just like gene cloning.Target speciﬁcity optimization
Point mutations in the two nuclease catalytic domains of Cas9,
HNH and RuvC, can convert Cas9 into a DNA nickase, which
is called Cas9 nickase [27,28]. Moreover, using double Cas9
nickases in combination with the sgRNAs targeting opposite
DNA strands of the target sites can cause DSBs with low
off-target activity [57]. Quantitative analysis showed that
Cas9 nickase could reduce off-target activity by 50–1500 folds
in various cell lines [57]. The high target speciﬁcity of Cas9
nickase was further veriﬁed by Skarnes’ group. They found
no detectable NHEJ-induced damage at the reported off-
target sites recognized by wild-type Cas9 endonuclease both
in mouse embryos and cultured cells [58]. Another successful
example for SpCas9 mutant is the recently-reported ‘‘enhanced
speciﬁcity” SpCas9 (eSpCas9) variants generated based on
structure-guided protein engineering. eSpCas9 can maintain
on-target efﬁciency and exhibit improved speciﬁcity [59].
Similar to ZFNs and TALENs, the smart combination of
the inactive Cas9 protein (dCas9) and FokI nucleases was
developed by two groups at the same time [55,60]. In the
FokI-based CRISPR/Cas system, the FokI nuclease domain
is fused to a catalytically-inactive Cas9 protein. After being
recruited by two gRNAs, the dimers of the FokI fusion protein
mediate sequence-speciﬁc DNA cleavage, with a deﬁned spac-
ing and orientation [55,60]. Quantitatively, the speciﬁcity of
the FokI-based CRISPR/Cas was at least 140 fold higher than
that of the wild type Cas9, and even fourfold higher than that
of Cas9 nickase at similar endogenous off-target loci [60].
Recently, it was shown that SpCas9 can be modiﬁed with
altered PAM speciﬁcity in zebraﬁsh embryos and human cells.
The speciﬁcity of a SpCas9 variant containing non-canonicalNAG and NGA was increased in human cells [61]. In sum-
mary, both Cas9 nickase and FokI-based CRISPR/Cas can
improve DNA cleavage speciﬁcity with lower off-target activ-
ity, which makes highly speciﬁc genome-wide editing much
easier.
Inducible CRISPR system
Conditional mutagenesis is often necessary to uncover the
mechanism of gene function. Efforts to modify the efﬁciency
and speciﬁcity of the CRISPR/Cas system also involve control
of Cas9 nuclease activity in a spatial and temporal manner.
Firstly, the inducible CRISPR (iCRISPR) system, composed
of doxycycline-regulated Cas9 and a speciﬁc gRNA, was devel-
oped for genome editing in human pluripotent stem cells
(hPSCs) and adult mice, and for generation of stage-speciﬁc
inducible gene knockouts [62–64]. In addition, low copy
expression of the rapamycin-inducible split-Cas9, composed
of Cas9(N)-FK506 binding protein 12 (FKBP) rapamycin
binding (FRB) and Cas9(C)-FKBP, can induce mutations at
EMX1 loci, while split dCas9-VP64 can mediate inducible
transcription activation in HEK293FT cells [65]. Furthermore,
photoactivatable Cas9 (paCas9) that responds to blue light
irradiation was generated on the basis of split-Cas9 and
photo-inducible dimerization domains named Magnets.
paCas9 has been exploited and validated for efﬁcient genome
editing in human cells [66]. The greatest advantage of this sys-
tem is its spatiotemporal and reversible feature, making it a
potential alternate to the Cre-loxP system in generating condi-
tional knockouts in vivo. Moreover, paCas9 and speciﬁc
gRNAs targeting different endogenous genes may facilitate
multiple gene knock-outs in vivo in a spatiotemporal manner,
which would be much easier than other systems.
Gene regulation by dCas9 fused with effector domains
In addition to genome editing, a modiﬁed form of Cas9 that
lacks the endonuclease activity, dead Cas9 (dCas9), was ﬁrst
shown to regulate endogenous gene expression in Escherichia
coli and mammalian cells [67]. This system, called CRISPR
interference (CRISPRi), can repress the expression of targeted
genes. Soon after, dCas9 was fused to effector domains with
distinct regulatory functions for stable and efﬁcient repression
or activation at the transcriptional level in human and yeast
cells [68]. The speciﬁcity of CRISPRi-mediated transcriptional
regulation was determined solely by the co-expressed short
gRNA that can recognize the endogenous target gene.
dCas9-KRAB or dCas9-VP160 was used to alter expression
of the endogenous dpy-5 and dbl-1 in C. elegans or fgf8a and
foxi1 in zebraﬁsh embryos, respectively [69]. More impor-
tantly, the modiﬁed photoactivatable dCas9 (padCas9) system
can reversibly control spatiotemporal expression of endoge-
nous genes [66].
Cas9 is an RNA-guided DNA endonuclease, which requires
a short DNA sequence named PAM for binding and catalysis.
It was found, however, that Cas9 can also bind to single-
stranded RNA (ssRNA) in the presence of specially-designed
PAM-presenting oligonucleotides (PAMmers) and a matching
gRNA, leading to site-speciﬁc cleavage of ssRNA targets while
ignoring the corresponding DNA sequences [70]. In addition,
dCas9 with speciﬁcally designed 50-extended PAMmers and
Ma D and Liu F /Genome Editing in Model Organisms 341gRNA can target non-PAM sites on GADPH mRNA, allow-
ing this mRNA to be puriﬁed from HeLa cells in a tagless
manner [70]. Therefore, programmable RNA recognition by
CRISPR/Cas can be used as a candidate approach for speciﬁc
endogenous mRNA isolation, analysis, and manipulation in
the absence of afﬁnity tags [70]. The dCas9 not only expands
the application of CRISPR/Cas to areas other than genome
editing, but also provides a candidate method for spatiotempo-
ral and reversible gene regulation in vivo, with the help of pad-
Cas9 controlled by blue light irradiation.Generation of disease models using CRISPR/Cas
In addition to site-speciﬁc modiﬁcations in the genomes,
TALENs and CRISPR/Cas also have potential applications
in disease models and gene correction. First, human stem
cell-based disease models were generated using TALENs,
and different disease-related genes were analyzed, including
APOB for human hepatitis C virus (HCV) replication, SORT1
(encoding sortilin) for ApoB secretion in hepatocytes, insulin
resistance in adipocytes and motor neuron death, and PLIN1
for lipolysis in adipocytes [71]. More importantly, heritable
disease models have been easily generated. For instance,
lentivirus-delivered sgRNA:Cas9 genome editing was used to
generate mouse models of myeloid malignancy by modifying
ﬁve genes in mouse hematopoietic stem cell (HSC) [72]. And
a cancer model was also generated using the CRISPR/Cas sys-
tem by targeting tumor suppressor genes pten and p53 in liver
[73]. As for zebraﬁsh disease models, a rps19 null mutant was
generated using TALENs to reproduce the erythroid defects of
Diamond–Blackfan anemia (DBA) [74]. Recently, human hep-
atic cutaneous porphyria was mimicked by a tissue-speciﬁc
gene inactivation system resulting from disruption of the urod
gene using a different tissue-speciﬁc promoter [47].
Using CRISPR/Cas system, Liu’s group generated a series
of mutations in the blood development related genes of zebra-
ﬁsh, including ncor2 [75], runx1, runx3, rac2, and klf6a (unpub-
lished data), that could be used to model human hematological
diseases, including bone marrow failure, anemia, and
myelodysplasia syndrome (MDS). The Zebraﬁsh All Genes
KO Consortium for Chromosome 1 (ZAKOC) has been estab-
lished with the efforts of nearly all the zebraﬁsh labs in China
since June 2013. This project would accumulate zebraﬁsh
mutant resources for basic sciences and also for disease
modeling.
Gene therapy on clinical mutations and disease
models
Gene therapy, based on therapeutic delivery of nucleic acid
polymers into patient, is an innovative method that has gener-
ated much controversy. Development of CRISPR/Cas and
TALENs makes gene therapy more feasible and easier in the
treatment of diseases. CRISPR/Cas was ﬁrstly used for efﬁ-
cient correction of disease-related genes in mouse and intesti-
nal stem cells of a cystic ﬁbrosis (CF) patient at the end of
2013 [76]. Clevers’s group cultured intestinal (LI) stem cells
from CF patients homozygous for the most common cystic
ﬁbrosis transmembrane conductance regulator (CFTR)
mutations and used CRISPR/Cas-mediated homologousrecombination to correct the CFTR locus. Their data indicated
that the corrected allele could be detected and was conﬁrmed
to be functional [77]. A single nucleotide deletion in exon 3
of the Crygc gene in mice leads to the generation of a stop
codon at the 76th amino acid residue. Mice with the resulting
dominant gene mutation serve as a model of dominant catar-
act disorder [76,77]. Li’s group showed that the mutation in
Crygc can be corrected at the organismal level through
HDR, by co-injecting Cas9 mRNA, together with a speciﬁc
gRNA targeting the mutant allele with exogenously-supplied
oligonucleotide, into zygotes [76]. Further analysis showed
that the mouse carrying the corrected mutation was fertile
and able to transmit the modiﬁed DNA sequence to its pro-
geny [76]. To date, there are a number of disease models
reported to be corrected successfully using CRISPR/Cas-
mediated homologous recombination, such as the Fah muta-
tion in mouse hepatocytes [78] and the mdx mutation in the
mice model for Duchene muscular dystrophy (DMD) [79].
b-thalassemia, caused by mutations in the adult b-globin
gene, is one of the most common genetic diseases worldwide
[80]. Pan’s group efﬁciently generated integration-free
b-thalassemia iPS cells from the cells of patients and cor-
rected b-globin gene (HBB) mutations in situ using TALENs
with a donor template harboring the entire wild type b-
globin gene [80]. Further study showed that the gene-
corrected b-thalassemia iPS cell lines from each patient had
restored HBB gene function in b-thalassemia-iPSC-derived
hematopoietic progenitor cells (HPCs) and erythroblasts
[80]. Later on, the HBB mutations in patient-derived iPSCs
was also efﬁciently corrected using CRISPR/Cas9 combined
with the piggyBac transposon without leaving a residual foot-
print. The corrected iPS cells were differentiated into ery-
throblasts with restored expression of HBB [81]. Fanconi
anemia is another blood disease in which gene correction
was attempted. The FANCC c.456 + 4A> T mutation in
patient-derived ﬁbroblasts was corrected using CRISPR/
Cas9 with a donor plasmid containing a ﬂoxed puromycin
and FANCC cDNA ﬂanked with arms that were homolo-
gous to the FANCC locus [82].
Conclusion and perspective
New tools for DNA manipulation, including TALENs and
CRISPR/Cas, not only make site-speciﬁc modiﬁcations in the
genomes much easier, but also revolutionize the classical
approaches for determining gene function due to their target
site speciﬁcity, ﬂexible design, and ease of operation. Tradi-
tional forward genetics approaches can generate mutants with
the desired phenotypes; however, the subsequent gene mapping
is very complicated, and it is not feasible to perform large-scale
genetic screens in some model organisms. Reverse genetics by
gene targeting usually employs ESCs, which are limited to a
few model systems, and the process is time-consuming. The
newly-emerging technologies for genome editing can, in princi-
pal, target any gene of interest; therefore, speciﬁc modiﬁcations
or targeted gene knockouts can be easily obtained in model
organisms. So far, CRISPR/Cas has been quickly optimized
and applied to most of the current model systems, and even
in the human tripronuclear zygotes (Figure 1).
The CRISPR/Cas system has been continuously improved
from different angles, including efﬁciency, speciﬁcity,
Table 3 Optimization of CRISPR/Cas9 system
Cas9 gRNA
Improvement Refs. Improvement Refs.
Eﬃciency Codon-optimized Cas9 [29,31,50] Modiﬁcation on 30 end of crRNA:tracrRNA chimera [31]
St1Cas9 and SaCas9 [28,51] Csy4-based gRNA cleavage [54,55]
Cpf1 [52] Chemically-modiﬁed gRNAs [56]
Speciﬁcity Cas9 nickase [57,58]
eSpCas9 [59]
FokI-based CRISPR/Cas [55,60]
Cas9 activity dCas9-KRAB and dCas9-VP160 [69]
Photoactivatable dCas9 [66]
Spatiotemporal control Speciﬁc promoter driven Cas9 [47]
Doxycycline-regulated Cas9 [62–64]
Rapamycin-inducible split-Cas9 [65]
Photoactivatable Cas9 [66]
Note: Cas9, CRISPR-associated protein 9; St1Cas9, Streptococcus thermophilus Cas9; SaCas9, Staphylococcus aureus Cas9; Cpf1, Cas protein 1 of
PreFran subtype; eSpCas9, ‘‘enhanced speciﬁcity” Streptococcus pyogenes type II Cas9; dCas9, catalytically inactive Cas9; KRAB,
Kru¨ppel associated box; gRNA, guide RNA; crRNA, CRISPR RNA; tracrRNA, trans-activating crRNA; Csy4, CRISPR subtype Ypest protein 4.
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(Table 3). Until now, the CRISPR/Cas system not only
improves basic research but also has potential applications
in gene therapy through gene repair, gene disruption, and
programmable RNA targeting [32]. However, there are also
some disadvantages and controversial issues, for example,
the off-target effect. To solve this problem, the chemically-
modiﬁed gRNAs, Cas9 nickase, FokI-based CRISPR/Cas,
and eSpCas9 can be harnessed to reduce off-target and
improve the speciﬁcity.
For the clinical application of CRISPR/Cas in future,
many points should be considered. The ﬁrst question is
how to guarantee the efﬁciency. In spite of the improvements
on Cas9 and the gRNAs, the low efﬁciency of HDR after
Cas9-mediated DNA cutting is a challenge. Importantly, it
has been shown that inhibiting NHEJ-mediated repair
enhances HDR for the insertion of precise genetic modiﬁca-
tions by the inhibitor, Scr7 targeted DNA ligase IV, or by
key molecules involved in gene silencing [83,84]. The next
question is how to deliver Cas9 and gRNAs to cells, espe-
cially to adult tissues. Fortunately, the shorter form of
Cas9 in the AAV vector, nucleofection, cell-penetrating pep-
tides, and the inducible Cas9 have been developed, which will
provide candidate approaches for gene therapy in adult
[85,86]. Finally, the most controversial question is whether
CRISPR/Cas can be used in humans ethically and safely.
As Jennifer Doudna, a pioneer of CRISPR/Cas technology,
pointed out, that with the rapid development of this technol-
ogy and its wide application, the philosophical and ethical
ramiﬁcations for altering genomes, especially on the modiﬁ-
cation of human germ cells and embryos should be very cau-
tious, and an international guideline on the proper use of
genome editing should be abided by the entire ﬁeld [87,88].
Overall, this ethical issue needs to be addressed by scientists
and society before CRISPR/Cas can be used in clinical gene
therapy and that CRISPR/Cas system also needs to be opti-
mized on various aspects to improve the efﬁciency and
speciﬁcity.Competing interests
The authors have no conﬂicts of interest to declare.Acknowledgments
We thank Dr. Bo Zhang for critical reading of this manuscript.
This work was supported by grants from the National Basic
Research Program of China (Grant Nos. 2010CB945300 and
2011CB943900), the National Natural Science Foundation of
China (Grant Nos. 31271570, 31425016, 31370030, and
81530004), and the Strategic Priority Research Program of
the Chinese Academy of Sciences (Grant No. XDA01010110).
References
[1] Travis J. Making the cut. Science 2015;350:1456–7.
[2] Bibikova M, Beumer K, Trautman JK, Carroll D. Enhancing
gene targeting with designed zinc ﬁnger nucleases. Science
2003;300:764.
[3] Bibikova M, Golic M, Golic KG, Carroll D. Targeted chromo-
somal cleavage and mutagenesis in Drosophila using zinc-ﬁnger
nucleases. Genetics 2002;161:1169–75.
[4] Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes:
zinc ﬁnger fusions to Fok I cleavage domain. Proc Natl Acad Sci
U S A 1996;93:1156–60.
[5] Strobel SA, Dervan PB. Site-speciﬁc cleavage of a yeast chromo-
some by oligonucleotide-directed triple-helix formation. Science
1990;249:73–5.
[6] Gottesfeld JM, Neely L, Trauger JW, Baird EE, Dervan PB.
Regulation of gene expression by small molecules. Nature
1997;387:202–5.
[7] Yang J, Zimmerly S, Perlman PS, Lambowitz AM. Efﬁcient
integration of an intron RNA into double-stranded DNA by
reverse splicing. Nature 1996;381:332–5.
[8] Gaj T, Gersbach CA, Barbas 3rd CF. ZFN, TALEN, and
CRISPR/Cas-based methods for genome engineering. Trends
Biotechnol 2013;31:397–405.
Ma D and Liu F /Genome Editing in Model Organisms 343[9] Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD,
et al. Targeted gene knockout in mammalian cells by using
engineered zinc-ﬁnger nucleases. Proc Natl Acad Sci U S A
2008;105:5809–14.
[10] Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M,
DeKelver RC, et al. Efﬁcient targeting of expressed and silent
genes in human ESCs and iPSCs using zinc-ﬁnger nucleases. Nat
Biotechnol 2009;27:851–7.
[11] Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah
GE, et al. Heritable targeted gene disruption in zebraﬁsh using
designed zinc-ﬁnger nucleases. Nat Biotechnol 2008;
26:702–8.
[12] Capecchi MR. Gene targeting in mice: functional analysis of the
mammalian genome for the twenty-ﬁrst century. Nat Rev Genet
2005;6:507–12.
[13] Gu K, Yang B, Tian D, Wu L, Wang D, Sreekala C, et al. R gene
expression induced by a type-III effector triggers disease resistance
in rice. Nature 2005;435:1122–5.
[14] Romer P, Hahn S, Jordan T, Strauss T, Bonas U, Lahaye T. Plant
pathogen recognition mediated by promoter activation of the
pepper Bs3 resistance gene. Science 2007;318:645–8.
[15] Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S,
et al. Breaking the code of DNA binding speciﬁcity of TAL-type
III effectors. Science 2009;326:1509–12.
[16] Moscou MJ, Bogdanove AJ. A simple cipher governs DNA
recognition by TAL effectors. Science 2009;326:1501.
[17] Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, et al. A
TALE nuclease architecture for efﬁcient genome editing. Nat
Biotechnol 2011;29:143–8.
[18] Zhang F, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P.
Efﬁcient construction of sequence-speciﬁc TAL effectors for
modulating mammalian transcription. Nat Biotechnol
2011;29:149–53.
[19] Huang P, Xiao A, Zhou M, Zhu Z, Lin S, Zhang B. Heritable
gene targeting in zebraﬁsh using customized TALENs. Nat
Biotechnol 2011;29:699–700.
[20] Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt
C, et al. Efﬁcient design and assembly of custom TALEN and
other TAL effector-based constructs for DNA targeting. Nucleic
Acids Res 2011;39:e82.
[21] Cermak T, Starker CG, Voytas DF. Efﬁcient design and assembly
of custom TALENs using the Golden Gate platform. Methods
Mol Biol 2015;1239:133–59.
[22] Briggs AW, Rios X, Chari R, Yang L, Zhang F, Mali P, et al.
Iterative capped assembly: rapid and scalable synthesis of repeat-
module DNA such as TAL effectors from individual monomers.
Nucleic Acids Res 2012;40:e117.
[23] Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK.
FLASH assembly of TALENs for high-throughput genome
editing. Nat Biotechnol 2012;30:460–5.
[24] Schmid-Burgk JL, Schmidt T, Kaiser V, Honing K, Hornung V.
A ligation-independent cloning technique for high-throughput
assembly of transcription activator-like effector genes. Nat
Biotechnol 2013;31:76–81.
[25] Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P,
Moineau S, et al. CRISPR provides acquired resistance against
viruses in prokaryotes. Science 2007;315:1709–12.
[26] Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ,
Snijders AP, et al. Small CRISPR RNAs guide antiviral defense in
prokaryotes. Science 2008;321:960–4.
[27] Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA,
Charpentier E. A programmable dual-RNA-guided DNA
endonuclease in adaptive bacterial immunity. Science
2012;337:816–21.
[28] Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al.
Multiplex genome engineering using CRISPR/Cas systems.
Science 2013;339:819–23.[29] Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al.
RNA-guided human genome engineering via Cas9. Science
2013;339:823–6.
[30] Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang
F, et al. One-step generation of mice carrying mutations in
multiple genes by CRISPR/Cas-mediated genome engineering.
Cell 2013;153:910–8.
[31] Jao LE, Wente SR, Chen W. Efﬁcient multiplex biallelic zebraﬁsh
genome editing using a CRISPR nuclease system. Proc Natl Acad
Sci U S A 2013;110:13904–9.
[32] Doudna JA, Charpentier E. Genome editing. The new frontier of
genome engineering with CRISPR–Cas9. Science
2014;346:1258096.
[33] Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD,
et al. Efﬁcient genome editing in zebraﬁsh using a CRISPR–Cas
system. Nat Biotechnol 2013;31:227–9.
[34] Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, et al. Genome
editing with RNA-guided Cas9 nuclease in zebraﬁsh embryos.
Cell Res 2013;23:465–72.
[35] Bassett AR, Tibbit C, Ponting CP, Liu JL. Highly efﬁcient
targeted mutagenesis of Drosophila with the CRISPR/Cas9
system. Cell Rep 2013;4:220–8.
[36] Friedland AE, Tzur YB, Esvelt KM, Colaiacovo MP, Church
GM, Calarco JA. Heritable genome editing in C. elegans via a
CRISPR–Cas9 system. Nat Methods 2013;10:741–3.
[37] Li JF, Norville JE, Aach J, McCormack M, Zhang D, Bush J,
et al. Multiplex and homologous recombination-mediated genome
editing in Arabidopsis and Nicotiana benthamiana using guide
RNA and Cas9. Nat Biotechnol 2013;31:688–91.
[38] Hu X, Chang N, Wang X, Zhou F, Zhou X, Zhu X, et al.
Heritable gene-targeting with gRNA/Cas9 in rats. Cell Res
2013;23:1322–5.
[39] Nakayama T, Fish MB, Fisher M, Oomen-Hajagos J, Thomsen
GH, Grainger RM. Simple and efﬁcient CRISPR/Cas9-mediated
targeted mutagenesis in Xenopus tropicalis. Genesis
2013;51:835–43.
[40] Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al.
Generation of gene-modiﬁed cynomolgus monkey via Cas9/RNA-
mediated gene targeting in one-cell embryos. Cell
2014;156:836–43.
[41] Wagner JC, Platt RJ, Goldﬂess SJ, Zhang F, Niles JC. Efﬁcient
CRISPR–Cas9-mediated genome editing in Plasmodium falci-
parum. Nat Methods 2014;11:915–8.
[42] Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, et al.
CRISPR/Cas9-mediated gene editing in human tripronuclear
zygotes. Protein Cell 2015;6:363–72.
[43] Liu D, Wang Z, Xiao A, Zhang Y, Li W, Zu Y, et al. Efﬁcient
gene targeting in zebraﬁsh mediated by a zebraﬁsh-codon-
optimized cas9 and evaluation of off-targeting effect. J Genet
Genomics 2014;41:43–6.
[44] Auer TO, Duroure K, De Cian A, Concordet JP, Del Bene F.
Highly efﬁcient CRISPR/Cas9-mediated knock-in in zebraﬁsh by
homology-independent DNA repair. Genome Res
2014;24:142–53.
[45] Hruscha A, Krawitz P, Rechenberg A, Heinrich V, Hecht J, Haass
C, et al. Efﬁcient CRISPR/Cas9 genome editing with low off-
target effects in zebraﬁsh. Development 2013;140:4982–7.
[46] Li J, Zhang BB, Ren YG, Gu SY, Xiang YH, Du JL. Intron
targeting-mediated and endogenous gene integrity-maintaining
knockin in zebraﬁsh using the CRISPR/Cas9 system. Cell Res
2015;25:634–7.
[47] Ablain J, Durand EM, Yang S, Zhou Y, Zon LI. A CRISPR/Cas9
vector system for tissue-speciﬁc gene disruption in zebraﬁsh. Dev
Cell 2015;32:756–64.
[48] Yin L, Maddison LA, Li M, Kara N, LaFave MC, Varshney GK,
et al. Multiplex conditional mutagenesis using transgenic expres-
sion of Cas9 and sgRNAs. Genetics 2015;200:431–41.
344 Genomics Proteomics Bioinformatics 13 (2015) 336–344[49] Shah AN, Davey CF, Whitebirch AC, Miller AC, Moens CB.
Rapid reverse genetic screening using CRISPR in zebraﬁsh. Nat
Methods 2015;12:535–40.
[50] Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, et al. Generation of
gene-modiﬁed mice via Cas9/RNA-mediated gene targeting. Cell
Res 2013;23:720–3.
[51] Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ,
et al. In vivo genome editing using Staphylococcus aureus Cas9.
Nature 2015;520:186–91.
[52] Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM,
Makarova KS, Essletzbichler P, et al. Cpf1 is a single RNA-
guided endonuclease of a class 2 CRISPR–Cas system. Cell
2015;163:759–71.
[53] Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK. Improving
CRISPR–Cas nuclease speciﬁcity using truncated guide RNAs.
Nat Biotechnol 2014;32:279–84.
[54] Qin W, Liang F, Feng Y, Bai H, Yan R, Li S, et al. Expansion of
CRISPR/Cas9 genome targeting sites in zebraﬁsh by Csy4-based
RNA processing. Cell Res 2015;25:1074–7.
[55] Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon
D, et al. Dimeric CRISPR RNA-guided FokI nucleases for highly
speciﬁc genome editing. Nat Biotechnol 2014;32:569–76.
[56] Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S,
et al. Chemically modiﬁed guide RNAs enhance CRISPR–Cas
genome editing in human primary cells. Nat Biotechnol
2015;33:985–9.
[57] Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S,
Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9
for enhanced genome editing speciﬁcity. Cell 2013;154:1380–9.
[58] Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, et al.
Efﬁcient genome modiﬁcation by CRISPR–Cas9 nickase with
minimal off-target effects. Nat Methods 2014;11:399–402.
[59] Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F.
Rationally engineered Cas9 nucleases with improved speciﬁcity.
Science 2016;351:84–8.
[60] Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically
inactive Cas9 to FokI nuclease improves the speciﬁcity of genome
modiﬁcation. Nat Biotechnol 2014;32:577–82.
[61] Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT,
Zheng Z, et al. Engineered CRISPR–Cas9 nucleases with altered
PAM speciﬁcities. Nature 2015;523:481–5.
[62] Zhu Z, Gonzalez F, Huangfu D. The iCRISPR platform for rapid
genome editing in human pluripotent stem cells. Methods
Enzymol 2014;546:215–50.
[63] Gonzalez F, Zhu Z, Shi ZD, Lelli K, Verma N, Li QV, et al. An
iCRISPR platform for rapid, multiplexable, and inducible genome
editing in human pluripotent stem cells. Cell Stem Cell
2014;15:215–26.
[64] Dow LE, Fisher J, O’Rourke KP, Muley A, Kastenhuber ER,
Livshits G, et al. Inducible in vivo genome editing with CRISPR–
Cas9. Nat Biotechnol 2015;33:390–4.
[65] Zetsche B, Volz SE, Zhang F. A split-Cas9 architecture for
inducible genome editing and transcription modulation. Nat
Biotechnol 2015;33:139–42.
[66] Nihongaki Y, Kawano F, Nakajima T, Sato M. Photoactivatable
CRISPR–Cas9 for optogenetic genome editing. Nat Biotechnol
2015;33:755–60.
[67] Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin
AP, et al. Repurposing CRISPR as an RNA-guided platform for
sequence-speciﬁc control of gene expression. Cell
2013;152:1173–83.
[68] Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE,
et al. CRISPR-mediated modular RNA-guided regulation of
transcription in eukaryotes. Cell 2013;154:442–51.
[69] Long L, Guo H, Yao D, Xiong K, Li Y, Liu P, et al. Regulation
of transcriptionally active genes via the catalytically inactive Cas9
in C. elegans and D. rerio. Cell Res 2015;25:638–41.[70] O’Connell MR, Oakes BL, Sternberg SH, East-Seletsky A,
Kaplan M, Doudna JA. Programmable RNA recognition and
cleavage by CRISPR/Cas9. Nature 2014;516:263–6.
[71] Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K, et al.
A TALEN genome-editing system for generating human stem cell-
based disease models. Cell Stem Cell 2013;12:238–51.
[72] Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV,
McConkey ME, et al. Generation of mouse models of myeloid
malignancy with combinatorial genetic lesions using CRISPR–
Cas9 genome editing. Nat Biotechnol 2014;32:941–6.
[73] Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T,
Joshi NS, et al. CRISPR-mediated direct mutation of cancer genes
in the mouse liver. Nature 2014;514:380–4.
[74] Zhang Y, Ear J, Yang Z, Morimoto K, Zhang B, Lin S. Defects of
protein production in erythroid cells revealed in a zebraﬁsh
Diamond–Blackfan anemia model for mutation in RPS19. Cell
Death Dis 2014;5:e1352.
[75] Wei Y, Ma D, Gao Y, Zhang C, Wang L, Liu F. Ncor2 is required
for hematopoietic stem cell emergence by inhibiting Fos signaling
in zebraﬁsh. Blood 2014;124:1578–85.
[76] Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S, et al.
Correction of a genetic disease in mouse via use of CRISPR–Cas9.
Cell Stem Cell 2013;13:659–62.
[77] Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T,
et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal
stem cell organoids of cystic ﬁbrosis patients. Cell Stem Cell
2013;13:653–8.
[78] Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M,
et al. Genome editing with Cas9 in adult mice corrects a disease
mutation and phenotype. Nat Biotechnol 2014;32:551–3.
[79] Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R,
Olson EN. Prevention of muscular dystrophy in mice by CRISPR/
Cas9-mediated editing of germline DNA. Science
2014;345:1184–8.
[80] Ma N, Liao B, Zhang H, Wang L, Shan Y, Xue Y, et al.
Transcription activator-like effector nuclease (TALEN)-mediated
gene correction in integration-free beta-thalassemia induced
pluripotent stem cells. J Biol Chem 2013;288:34671–9.
[81] Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, et al.
Seamless gene correction of beta-thalassemia mutations in
patient-speciﬁc iPSCs using CRISPR/Cas9 and piggyBac. Gen-
ome Res 2014;24:1526–33.
[82] Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN,
Jarjour J, et al. Fanconi anemia gene editing by the CRISPR/Cas9
system. Hum Gene Ther 2015;26:114–26.
[83] Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K,
et al. Increasing the efﬁciency of homology-directed repair for
CRISPR–Cas9-induced precise gene editing in mammalian cells.
Nat Biotechnol 2015;33:543–8.
[84] Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram
JR, Ploegh HL. Increasing the efﬁciency of precise genome editing
with CRISPR–Cas9 by inhibition of nonhomologous end joining.
Nat Biotechnol 2015;33:538–42.
[85] Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efﬁcient RNA-
guided genome editing in human cells via delivery of puriﬁed Cas9
ribonucleoproteins. Genome Res 2014;24:1012–9.
[86] Ramakrishna S, Kwaku Dad AB, Beloor J, Gopalappa R, Lee
SK, Kim H. Gene disruption by cell-penetrating peptide-mediated
delivery of Cas9 protein and guide RNA. Genome Res
2014;24:1020–7.
[87] Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church
G, et al. Biotechnology. A prudent path forward for genomic
engineering and germline gene modiﬁcation. Science
2015;348:36–8.
[88] Doudna J. Genome-editing revolution: my whirlwind year with
CRISPR. Nature 2015;528:469–71.
